Since the DSMB conducts the interim analysis, if leronlimab is vastly superior at n=195 and gets under the pre-specified p-value boundary, the trial will be halted for efficacy; we won't know full/exact results until a couple of weeks later, but soon after the meeting we will know if the trial was a success...